Hansa Biopharma, a commercial-stage biopharmaceutical company, plans to restructure the organization to better align and focus on key clinical development and commercial priorities. The planned restructuring would result in an approximately 20-25% reduction in the current workforce and will result in approximately 75-85 million Swedish Krona in annual savings when implemented. The restructuring is subject to negotiation with relevant trade unions.

As part of the restructuring, Hansa will notify the Swedish Public Employment Service and seek consultations with the trade unions regarding the reorganization.

Søren Tulstrup, President and CEO, Hansa Biopharma said, “This planned restructuring is an important step in our ongoing efforts to optimize our investment in key value-creating growth opportunities and position the company for long-term success. While we firmly believe this initiative is a necessary action to help us deliver on our mission, it is a difficult decision as it impacts our most valuable asset, our people.”